Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press34510.17650/1726-9776-2012-8-2-87-91PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫHORMONE REFRACTORY PROSTATE CANCER AND ITS DEVELOPMENT DURING ANTIANDROGEN THERAPYГОРМОНАЛЬНАЯ РЕФРАКТЕРНОСТЬ ПРИ РАКЕ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ И ЕЕ РАЗВИТИЕ НА ФОНЕ АНТИАНДРОГЕННОЙ ТЕРАПИИRakulS. A.РакулС. А.
Russian Federation
garustam@yandex.ruGalimovR. D.ГалимовР. Д.
Russian Federation
garustam@yandex.ruCiti Hospital Forty, Saint PetersburgГородская больница № 40, Санкт-Петербург300620128287910608201406082014https://oncourology.abvpress.ru/oncur/article/view/345

Mechanisms of development of hormone refractory prostate cancer currently not fully understood.

Materials and methods: treatment results of 135 prostate cancer patients underwent subcapsular orchiectomy.

Results: hormone resistance registered at 38 (28.15%) patients, were sensitive to anti-androgenic therapy 97 (71.85%) patients. There are reliable differences between the probability of development of hormone refractory and the patient's age, disease stage and degree of tumor cell differentiation.

Conclusion: сlinical developed, laboratory and pathomorphological criteria, the use of which may reliably predict the likelihood of hormone refractory patients with prostate cancer on the background of antiandrogenic treatment.

Механизмы развития гормональной рефрактерности в настоящее время окончательно не изучены.

Материалы и методы. Результаты лечения 135 больных раком предстательной железы (РПЖ), которым выполнена субкапсулярная орхиэктомия.

Результаты. Гормональная рефрактерность развилась у 38 (28,15 %) пациентов, чувствительными к проведению антиандрогенной терапии остались 97 (71,85 %) пациентов. Отмечены достоверные различия между вероятностью развития гормональной рефрактерности и возрастом пациента, стадией заболевания и степенью клеточной дифференцировки опухоли.

Заключение. Разработаны клинические, лабораторные и патоморфологические критерии, используя которые возможно достоверно прогнозировать вероятность развития гормональной рефрактерности у больных РПЖ на фоне антиандрогенного лечения.

prostate cancerhormone resistanceantiandrogen therapyрак предстательной железыгормональная рефрактерностьантиандрогенная терапия1. Переверзев А.С., Коган М.И. Рак простаты. Харьков: Факт, 2004. 231 с.Переверзев А.С., Коган М.И. Рак простаты. Харьков: Факт, 2004. 231 с.2. Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2009 году. М.: ФГУ «МНИОИ им. П.А. Герцена Росмедтехнологий», 2010. 196 с.Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2009 году. М.: ФГУ «МНИОИ им. П.А. Герцена Росмедтехнологий», 2010. 196 с.3. Nelen V. Epidemiology of prostate cancer. Recent Results Cancer Res 2007;175:1−8.Nelen V. Epidemiology of prostate cancer. Recent Results Cancer Res 2007;175:1−8.4. Oh W.K., Kantoff P.W. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998; 160:1220−9.Oh W.K., Kantoff P.W. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998; 160:1220−9.5. Bubley G.J., Carducci M., Dahut W. et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17(11):3461−7.Bubley G.J., Carducci M., Dahut W. et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17(11):3461−7.6. Heidenreich A., von Knobloch R., Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur Urol 2001;39(2):121−30.Heidenreich A., von Knobloch R., Hofmann R. Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur Urol 2001;39(2):121−30.7. Scher H.I., Halabi S., Tannock I. et al. Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommenda tions of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7):1148−59.Scher H.I., Halabi S., Tannock I. et al. Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommenda tions of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7):1148−59.8. Heidenreich A., Bolla M., Joniau S. et al. EAU Guidelines on Prostate Cancer. 2011.Heidenreich A., Bolla M., Joniau S. et al. EAU Guidelines on Prostate Cancer. 2011.9. Schrоder F.H. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrinemediated mechanisms. Eur Urol 2008; 53(6):1129−37.Schrоder F.H. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrinemediated mechanisms. Eur Urol 2008; 53(6):1129−37.10. Kim I.Y., Ahn H.J., Zelner D.J. et al. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumour grade in human prostate cancer tissues. Clin Cancer Res 1996;2(8):1255−61.Kim I.Y., Ahn H.J., Zelner D.J. et al. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumour grade in human prostate cancer tissues. Clin Cancer Res 1996;2(8):1255−61.11. Mohler J.L., Gregory C.W., Ford O.H. et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10(2):440−8.Mohler J.L., Gregory C.W., Ford O.H. et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10(2):440−8.12. Hu R., Dunn T.A., Wei S. et al. Ligandindependent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69(1):16−22.Hu R., Dunn T.A., Wei S. et al. Ligandindependent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009;69(1):16−22.13. Koivisto P.A., Schleutker J., Helin H. et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Clin Cancer Res 1999;5(11):3578−82.Koivisto P.A., Schleutker J., Helin H. et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Clin Cancer Res 1999;5(11):3578−82.14. Linja M.J., Savinainen K.J, Saramaki O.R. et al. Amplification and over expression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61(9):3550−5.Linja M.J., Savinainen K.J, Saramaki O.R. et al. Amplification and over expression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61(9):3550−5.15. Furuya Y., Krajewski S., Epstein J.I. et al. Expression of bcl-2 and the progression of human and rodent prostate cancers. Clin Cancer Res 1996;2(2):389−98.Furuya Y., Krajewski S., Epstein J.I. et al. Expression of bcl-2 and the progression of human and rodent prostate cancers. Clin Cancer Res 1996;2(2):389−98.16. Taplin M.E., Rajeshkumar B., Halabi S. et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. Clin Oncol 2003;21(14):2673−8.Taplin M.E., Rajeshkumar B., Halabi S. et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. Clin Oncol 2003;21(14):2673−8.